Mark Foundation   Report issue

Foundation Phase 2
Founded: New York NY United States (2017)

Organization Overview

First Clinical Trial
2019
NCT04093167
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Mark Foundation